2cureX

The aim is to develop stand-alone life-science solutions that are based on 2cureX's ChemoCellomics technology. DELTA will apply its multidisciplinary technical development capabilities to the joint product development.

Unique technology

2cureX's ChemoCellomics® is a unique technology that integrates synthesis of large collections of individual chemical compounds with screening thereof in intact living cells. An important feature of the technology is that it for the first time allows high throughput cell-based screening in primary cells taken directly from patients with chemical structures that previously have been overwhelmingly expensive to produce.

Ole Thastrup, CEO of 2cureX, says "We are delighted to have DELTA as a strategic partner. We are convinced that this partnership is crossing traditional technical and business barriers and will result in truly novel healthcare applications to the benefit of a broad spectrum of patients. In this partnership we will leverage some of the wide applications of the ChemoCellomics technology that lie outside 2cureX's internal drug discovery efforts. We see the partnership with DELTA as a clear indication of the breath of 2cureX's core technology".

Click here to have a look at 2cureX's homepagee.